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Background: Heart attack is the most common cause of line-of-duty death in the ﬁre service. Daily
aspirin therapy is a preventative measure used to reduce the morbidity of heart attacks but may decrease
the ability to dissipate heat by reducing skin blood ﬂow.
Methods: In this double-blind, placebo-controlled, crossover study, ﬁreﬁghters were randomized to
receive 14 days of therapy (81-mg aspirin or placebo) before performing treadmill exercise in thermal-
protective clothing in a hot room [38.8  2.1C, 24.9  9.1% relative humidity (RH)]. Three weeks without
therapy was provided before crossing to the other arm. Fireﬁghters completed a baseline skin blood-ﬂow
assessment via laser Doppler ﬂowmetry; skin was heated to 44C to achieve maximal cutaneous vaso-
dilation. Skin blood ﬂow was measured before and after exercise in a hot room, and at 0 minutes, 10
minutes, 20 minutes, and 30 minutes of recovery under temperature conditions (25.3  1.2C,
40.3  13.7% RH). Platelet clotting time was assessed before drug administration, and before and after
exercise.
Results: Fifteen ﬁreﬁghters completed the study. Aspirin increased clotting time before and after exercise
compared with placebo (p ¼ 0.003). There were no differences in absolute skin blood ﬂow between
groups (p ¼ 0.35). Following exercise, cutaneous vascular conductance (CVC) was 85  42% of maximum
in the aspirin and 76  37% in the placebo groups. The percentage of maximal CVC did not differ by
treatment before or after recovery. Neither maximal core body temperature nor heart rate responses to
exercise differed between trials.
Conclusion: There were no differences in skin blood ﬂow during uncompensable heat stress following
exercise after aspirin or placebo therapy.
Copyright  2015, Occupational Safety and Health Research Institute. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fireﬁghters have the highest occurrence of line-of-duty death in
the United States [1]. Over half of these deaths are cardiovascular
events directly related to ﬁre-suppression activities [2e4].
Continuous heavy work in thermal-protective clothing and repet-
itive upper body tool use characteristic of structural ﬁre suppres-
sion impose signiﬁcant cardiovascular strain by increasing
myocardial oxygen demand and decreasing myocardial oxygenysiology, College of Nursing and H
ntire).
upational Safety and Health Resear
by-nc-nd/4.0/).supply [5,6]. The physical strain combined with uncompensable
heat stress provides triggers for ischemic events (i.e., myocardial
infarction, stroke) [7e9].
Heart rate and core body temperature rise rapidly in response to
increased physical work and environmental heat stress, which ac-
tivates coagulation and causes vasoconstriction and endothelial
dysfunction [7e9]. In addition, shift work, lifestyle factors, and
exposure to smoke and chemicals during ﬁre suppression may
further predispose ﬁreﬁghters to earlier onset heart disease byealth Sciences, Valdosta State University, 1500 North Patterson Street, Valdosta, GA
ch Institute. Published by Elsevier Ltd. This is an open access article under the CC BY-
Table 1
Timeline of study visits
Study visit 1 Screening Informed consent, demographics,
screening, and exercise stress test
Study visit 2 Baseline and maximal
SBF, ASG
Resting LDF in heated room
(37.5e40C)
Iodine paper test for sweat
gland activation
Study drug No. 1 (14 d)
Study visit 3 Protocol 1 1. Baseline measurements
and preparation
2. Pre-exercise LDF, ASG
3. 45-min hot exercise
4. Postexercise LDF, ASG
5. 30-min recovery period
3-wk washout period before beginning second study medication
Study drug No. 2 (14 d)
Study visit 4 Protocol 2 1. Baseline measurements
and preparation
2. Pre-exercise LDF, ASG
3. 45-min hot exercise
4. Postexercise LDF, ASG
5. 30-min recovery period
ASG, activated sweat gland; LDF, laser Doppler ﬂowmetry; SBF, skin blood ﬂow.
S.J. McEntire et al / Thermoregulation in Fireﬁghters 257amplifying inﬂammation and endothelial dysfunction, a precursor
to atherosclerosis [10e13].
Our laboratory has completed a clinical trial investigating the
effects of low-dose aspirin therapy on ﬁreﬁghter physiology,
platelet activation, and vascular function during and following
uncompensable heat stress (clinicaltrials.gov NCT01066923).
Aspirin has been shown to reduce cardiac events in individuals of
the general population who have cardiovascular disease (CVD) risk
factors [14] and may decrease the overall prothrombotic state
resulting from exertional heat stress during ﬁre suppression. Data
from our laboratory have demonstrated that aspirin therapy blunts
heat-induced platelet activation and did not adversely affect core
body temperature during work in an uncompensable heat stress
environment [15]. However, other reports have suggested that
systemic platelet inhibition by aspirin with standard therapeutic
doses subsequently inhibited reﬂex cutaneous vasodilation [16e
18]. Speciﬁcally, anticoagulation therapy inhibits the release of
vasodilator substances from activated platelets [19e21], decreases
the shear stimulus on the cutaneous microvasculature [17], and/or
alters the internal temperature threshold for heat dissipation
[16,17], eventually resulting in decreased dry heat loss capacity and
increased thermal strain.
To our knowledge, this is the ﬁrst study to comprehensively
examine the effects of low-dose aspirin therapy on multiple indices
of thermoregulation, inﬂammation, and physiological responses to
exertion in the heat while wearing thermal-protective clothing.
Previous studies demonstrating an attenuation in skin blood-ﬂow
responses were primarily done under passive heat stress condi-
tions in middle-aged and older adults [16,17], with large doses of
aspirin [22], or using anodal current-induced vasodilation [18,22],
none of which is reﬂective of the environmental conditions or ex-
ertional loads that ﬁreﬁghters are exposed to. In addition, doing
exercise in the heat leads to total body water and plasma volume
losses, which further reduce blood ﬂow to the gut [23]. Hypo-
perfusion of the gut leads to mucosal damage and the invasion of
endotoxins into the blood. Low-dose aspirin has also been reported
todamage the gutmucosa [24,25]. Elevated endotoxin levels can lead
to fever, shivering, dizziness, nausea, vomiting, and diarrhea, all of
which have been reported in endurance athletes [26e28]. The level
of plasma tumor necrosis factor-a (TNF-a) is signiﬁcantly increased
in response to endotoxin [29]. Endotoxin and cytokine release may
be indicative of poor thermal compensation. Understanding the
impact of aspirin therapy on endotoxin release and the subsequent
cytokine response is vital with regard to the safety proﬁle of aspirin
use during exertion under uncompensable heat stress conditions.
This is important given that ﬁreﬁghters may use daily aspirin
therapy as primary prevention against heart attacks as well as to
treat minor pain; therefore, information on the effect of aspirin
during uncompensable heat stress is needed to make educated
decisions about preventative treatment of CVD. If aspirin is detri-
mental to some aspect of thermoregulation, then this can guide
physicians to treat the risk factors of CVD with other therapies and
provide critical information about the risk/beneﬁt ratio for aspirin
therapy in ﬁreﬁghters whether used in an occupational context or
for the management of CVD risk. This examination of the thermo-
regulatory, inﬂammatory, and physiological responses to low-dose
aspirin therapy in ﬁreﬁghters during and following exertion under
uncompensable heat stress conditions offers a more in-depth
assessment of the safety of its use in this occupational cohort.
2. Materials and methods
We conducted a double-blind, placebo-controlled, crossover
study to determine the additional effects of aspirin therapy on re-
ﬂex cutaneous vasodilation, core body temperature, and heart rateresponses under uncompensable heat stress conditions. Partici-
pants were volunteers and career ﬁreﬁghters from ﬁre departments
and emergency service agencies from Western Pennsylvania. All
participants had no history of CVD, did not use medications ex-
pected to blunt the physiologic response to treadmill exercise or
those with the known side effect of impaired thermoregulation,
medications or supplements known to alter endothelial function
(i.e., arginine, omega 3 fatty acids, nonsteroidal anti-inﬂammatory
drugs, tobacco), or had no known history of platelet dysfunction,
aspirin allergy/intolerance, or iodine allergy. The University of
Pittsburgh Institutional Review Board approved the study and all
participants provided written informed consent prior to
participation.
2.1. Screening
All participants received a physical examination from a study
physician including a 12-lead electrocardiogram (ECG) and a
treadmill exercise stress test. Height was determined using a sta-
diometer, weight was recorded on a digital scale accurate to 0.5 g
(KERN & SOHN GmbH, Balingen, Germany), and body fat was
measured using three-site skinfold measurements [30]. Exclusion
criteria included hypertension during screening and a resting ECG
depicting the presence or history of CVD.
A Bruce protocol treadmill test was used to determine aerobic
capacity (VO2max) with open-circuit spirometry (TrueOne 2400;
Parvo Medics, Sandy, UT, USA) measuring respiratory rate and
maximal oxygen consumption (VO2peak). Test results were inter-
preted by a board-certiﬁed cardiologist.
After meeting all inclusion criteria, a venous blood sample was
obtained fromeachparticipant forestimatingbaselineplatelet closure
time. The sample was stored for future assay for detecting levels of
endotoxin, interleukin-6 (IL-6), and TNF-a. Epinephrine-induced
platelet aggregability (platelet closure time) was determined in
whole-blood samples using a platelet function analyzer (PFA-100,
Siemens, Malvern, PA, USA). A timeline of study visits is presented in
Table 1.
2.2. Baseline skin blood ﬂow
Following the screening visit, all participants returned to our
laboratory for skin blood-ﬂow measurements to establish baseline
Saf Health Work 2015;6:256e262258and maximal values. To obtain an index of skin blood ﬂow, cuta-
neous red blood cell ﬂux was measured using an integrated laser-
Doppler ﬂowmeter (LDF) (PeriFlux System 5020; Perimed AB,
Stockholm, Sweden) placed on the volar aspect of the forearm. The
LDFmeasurements are speciﬁc to the skin and are not inﬂuenced by
underlying skeletal muscle blood ﬂow [31]. Blood pressure was
recorded on the contralateral arm. Cutaneous vascular conductance
(CVC) was indexed as LDF (V)/mean arterial pressure (mmHg).
Participants were dressed in shorts and a t-shirt and seated in a
semireclined position in a heated room [38.6  2.3C; 20.0  6.3%
relative humidity (RH)]. Oral temperature was taken to ensure all
participants were afebrile (<37.5C). Following 5 minutes of
steady-state resting measurement, the skin was heated from 36C
to 44C, with a steady-state 3-minute interval at each degree.
Participants were informed about the importance of remaining still
and not moving during the testing.
Prior to and immediately after obtaining the LDFmeasurements,
starch-impregnated paper was placed onto iodine-prepared skin
proximal to the LDF probe for assessment of the number of acti-
vated sweat glands (ASGs). The carbohydrates in sweat combine
with iodine to create a dark dot, which indicates an active sweat
gland. Four, 1-cm2 squares were counted and the average number
of ASGs was obtained [32e34]. Skin saturated with sweat was
wiped dry prior to paper placement. Measurements were also ob-
tained on both exercise protocol days.
Participants were randomized to receive low-dose aspirin
(81 mg) and placebo for 2 weeks in a double-blind, crossover
fashion. The UPMC Investigational Drug Service prepared the study
drugs by placing aspirin tablets into an opaque capsule with an
additional binder or by ﬁlling identical capsules with binder alone.
The masked drug was then dispensed to the research technicians
based on unique participant identiﬁcation codes. Participants were
given 15 capsules of the study drug and instructed to take one
capsule each day with water. A study coordinator contacted each
participant by phone or text message with reminders to take the
study drug. Participants returned the pill bottle at each protocol
visit to verify the number of pills taken.
2.3. Protocol visits
Protocol visits were scheduled 13e15 days after beginning the
study drug. Participants took an ingestible pill with a radio receiver
(HQ Inc, Palmetto, FL, USA) the night before the protocol for mea-
surement of core body temperature and to minimize the con-
founding effects of food or ﬂuid in the gastrointestinal tract. Fig. 1
depicts the timeline of events and data collection for the protocol
visits. Participants provided a urine sample for determination of
urine-speciﬁc gravity via a handheld refractometer (ATAGO U.S.A.,
Inc., Bellevue, WA, USA). If the value was >1.025, an additional
500 mL of water was consumed and participants rested quietly for
30 minutes prior to continuing with the protocol. A fasting venousFig. 1. Timeline of events during each protocol. ASG, activatedblood sample was provided for assessment of platelet closure time
and detection of endotoxin, IL-6, and TNF-a levels. A weight-based
standardized meal (PowerBar, Glendale, CA, USA; Clif Bar, Berkeley,
CA, USA) and 400e600mL of waterwere provided to ensure similar
pre-exercise nutrition prior to exercise. Participants were then
weighed nude.
A heart rate monitor was placed around the chest, and skin
temperature probes were placed over the sternal head of the pec-
toralismajor, supraspinatus, midpoint of the triceps brachii, and the
midpoint of the quadriceps femoris muscles. Mean skin tempera-
ture (Tsk) was calculated as follows: Tsk ¼ chest (0.25) þ back
(0.25) þ thigh (0.3) þ arm (0.2) [35]. The skin of the right forearm
was cleaned with deionized water and an LDF probe holder was
secured to the volar aspect. Next to the probe holder, iodine was
smeared onto the skin and allowed to dry for later ASG measure-
ment. Following instrumentation, participants donned station duty
pants, a cotton short-sleeve t-shirt, and thermal-protective clothing
for structural ﬁreﬁghting consisting of turnout pants (Body-Guard,
Lion Apparel, Dayton, OH, USA) and steel-toed rubber boots (Servus
Products, Rock Island, IL, USA).
The participants then entered the hot room (38.8  2.1C;
24.9  9.1% RH) and sat in a semireclined position for 10 minutes to
obtain LDF measurements. ASG assessment was carried out
immediately prior to obtaining skin blood-ﬂow measurement.
Following LDF, participants donned their thermal-protective coat
(Body-Guard, Lion Apparel), nomex hood (Majestic Fire Apparel,
Inc., Lehighton, PA, USA), polycarbonate helmet (Paul Conway,
Dayton, OH, USA), and leather gloves. They walked on a level
treadmill in the heated room for 45 minutes at 6.4 km/h (4.0 mi/h).
Heart rate, core body temperature, and skin temperature were
recorded every 5 minutes during exercise. Ratings of perceived
exertion, comfort, sweating, and thermal stress were also recorded
every 5 minutes during exercise using previously validated scales
[36]. Standardized instructions were provided prior to exercise
including examples of how to use the scales. Exercise ended when
participants completed the 45-minute protocol or when they
reached one of the following termination criteria: (1) participant
request; (2) heart rate exceeding 220e ageþ 10 bpm; (3) body core
temperature exceeding 39.5C; or (4) unsteady gait while walking
on the treadmill. Immediately following exercise, participants
removed their gloves, helmet, hood, and coat and sat in a semi-
reclined position for 10 minutes for LDF measurement and ASG
assessment.
The participant then exited the hot room to begin a 30-minute
recovery period in a temperate climate (25.3  1.2C;
40.313.7% RH). A venous blood samplewas drawn for assessment
of platelet closure time and future endotoxin detection. Skin blood
ﬂow, heart rate, blood pressure, core body, and skin temperature
were recorded every 5 minutes of the recovery period. Participants
were given 100 mL of water at 5 minutes, 15 minutes, and 25 mi-
nutes of recovery. ASG assessment was carried out prior to andsweat gland; HR, heart rate; LDF, laser Doppler ﬂowmetry.
Fig. 2. Skin blood ﬂow as a percentage of maximal cutaneous vasculature conductance
(CVC).
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removed and a nude weight was obtained. Sweat loss was calcu-
lated the change in body mass.
A 3-week washout period followed the ﬁrst drug protocol. After
the washout period, participants were given the other study drug
and instructed to follow the same procedures as before. Upon
completing the second study drug, participants returned to the
laboratory and repeated the aforementioned protocol.
2.4. Blood samples and assays
All blood samples were drawn using aseptic technique by
trained technicians. All blood samples, with the exception of the
platelet closure time sample, were placed immediately on ice for 10
minutes, and then centrifuged for 15e20 minutes at 3,500 rpm at
4C. The sample obtained to assess platelet closure time was
allowed to stand at room temperature for 10 minutes before
obtaining measurements. The endotoxin level was measured using
a sensitive and rapid chromogenic Limulus assay (Limulus amebo-
cyte lysate; QCL-100, Lonza, Walkersville, MD, USA). Levels of IL-6
and TNF-a were analyzed using a commercially available enzyme-
linked immunoassay (R&D Systems, Minneapolis, MN, USA).
2.5. Statistical analysis
Absolute maximal CVC was calculated as the average of a 3-
minute stable plateau in laser Doppler ﬂux following local heat-
ing of the skin to 44C with the CVC calculated and represented as
the percentage of maximum (%CVCmax). Two-way analysis of vari-
ance with repeated measures were conducted to determine dif-
ferences between trials in absolute CVC, %CVCmax, core
temperature, heart rate, skin temperature, activated sweat gland
count, endotoxin levels, and platelet clotting time. Paired t tests
were conducted to determine differences in the accelerometer
data, treadmill time, treadmill distance, and bodymass lost. Level of
signiﬁcance was set at a ¼ 0.05. All data are reported as
mean  standard deviation.
3. Results
Eighteen male ﬁreﬁghters were enrolled in the study. Two were
excluded from participation for medical reasons and one dropped
out due to a nonstudy-related illness (Table 2).
3.1. Skin blood-ﬂow assessment
During the baseline skin blood-ﬂow assessment and prior to
skin heating, absolute resting CVC was 0.26  0.27 V/mmHg, which
increased to a maximum of 2.44  0.57 V/mmHg. During the ex-
ercise protocols, absolute CVC demonstrated signiﬁcant and ex-
pected changes in both the aspirin and placebo trials, however,
these changes were not different between groups (p ¼ 0.35). There
were signiﬁcant changes over time in both the aspirin and placebo
groups in the percentage of maximal CVC achieved. Before exercise,Table 2
Demographics of the participants
Age (y) 30.5  9.3
Height (cm) 179.8  5.8
Weight (kg) 90.7  14.0
Body mass index (kg/m2) 27.9  3.7
Body fat (%) 15.7  5.3
VO2max (mL/kg/min) 46.6  7.0
All values are reported as mean  standard deviation.skin blood ﬂow in the aspirin trial was 20  38% of maximal CVC
and 23  42% of maximal CVC in the placebo trial. After exercise,
CVC was 85  42% of maximum in the aspirin trial and 76  37% in
the placebo trial. The percentage of maximal CVC did not differ
before the start of the recovery period in either the aspirin
(88  43%) or placebo (75  34%) trial. At the end of the 30-minute
recovery period, CVC was 62  38% of maximum in the aspirin trial
and 55  49% of maximum in the placebo trial (p ¼ 0.28; Fig. 2).3.2. Physiological variables
Core body temperature was not different between trials at any
time (p ¼ 0.69). After exercise, core temperature reached
39.0 0.7C in the aspirin trial and 39.10.6C in the placebo trial.
Core temperature continued to rise following exercise and reached
maximum values at the start of the recovery period in both the
aspirin (39.3  0.5C) and placebo (39.4  0.6C) trials. Core bodyFig. 3. Core body temperature responses.
Fig. 4. Heart rate responses.
Table 3
Activated sweat glands
Pre-exercise Postexercise Prerecovery Postrecovery
Placebo 1  1 71  62 56  79 14  23
Aspirin 2  3 63  68 57  56 10  22
All values are reported as mean  standard deviation.
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end of the 30-minute recovery period in both groups (Fig. 3).
Changes in heart rate over time were seen in both groups;
however, there were no group differences. Near-maximal heart
rates were achieved in both the aspirin (179 13 bpm) and placebo
(179  12 bpm) trials. Heart rate remained elevated in both groups
at the end of the recovery period (Fig. 4). There were no differences
in mean skin temperature between trials at any time point (Fig. 5).
Mass loss due to sweating was similar between the aspirin
(1.6  0.3 kg) and placebo (1.6  0.5 kg) trials. In addition, the
number of activated sweat glands during exercise was not different
between trials (Table 3). Total treadmill time and distance
completed were similar between trials. Similarly, accelerometer
data revealed that total calories expended, total metabolic equiv-
alents, and total steps were not different between trials (Table 4).
Participants did not report differences in perceptual ratings of
whole-body exertion, comfort, thermal sensation, or sweating
during exercise.
3.3. Blood markers
Platelet closure time increased after 14 days of aspirin therapy,
but did not change in the placebo trial. After exercise, plateletFig. 5. Skin temperature responses.closure time decreased to 114  24 seconds in the placebo trial and
to 210  82 seconds in the aspirin trial, demonstrating that low-
dose aspirin therapy partially attenuates exertional and heat
stress-related platelet activation. Compared with pre-exercise
levels, plasma endotoxin levels were increased after the exercise;
however, these levels were not different between the placebo or
aspirin trial. Hemoglobin level before exercise was higher in the
placebo trial compared with the aspirin trial (p ¼ 0.022); however,
there were no differences between groups after exercise. There
were no differences in hematocrit level before or after exercise or
between trials (p ¼ 0.749). Lactate levels after exercise were
signiﬁcantly increased compared with levels obtained before ex-
ercise in both drug trials (p ¼ 0.001; Table 5). The TNF-a and IL-6
levels were undetectable by immunoassay.
4. Discussion
Fourteen days of low-dose aspirin therapy blunts platelet acti-
vation under uncompensable heat stress condition. In this group of
young, healthy ﬁreﬁghters, there were no differences in skin blood-
ﬂow responses following exertion while wearing thermal-
protective clothing after aspirin therapy. Fireﬁghters reached
near-maximal heart rates, and their core body and skin tempera-
ture exceeded 39.0C at the end of exertion, which is similar to
what our laboratory has reported following live ﬁre exercises
[37,38].
Bruning et al [39] reported that core temperature was elevated
after passive heat stress and remained elevated following an ex-
ercise bout after 7 days of low-dose aspirin. However, therewere no
differences in the rate of rise in core body temperature or subjective
perception of effort between the aspirin and placebo trials. This is in
agreement with our results that there were no signiﬁcant differ-
ences in core body temperature, with both groups reaching tem-
peratures above 39.0C. Bruning et al [39] also reported a reduction
in CVCmax of approximately 10% and a rightward shift in the
threshold for the onset of reﬂex vasodilation following aspirin
therapy. We did not ﬁnd this to be true in our experiment. This may
be due to differences in the mode of exercise (cycle vs. treadmill),
higher exercise intensity resulting in higher maximal heart rates
and core body temperature during exercise, and uncompensable
heat stress conditions in our report.
We speculate that the uncompensable heat stress environment
created by thermal-protective clothing and the hot environmental
conditions in both treatment trials was the cause of the lack of
differences in skin blood-ﬂow response between groups in this
study. Encapsulation resulted in signiﬁcant sweat losses (>1-kg
mass lost) without body cooling, leading to a rise in core bodyTable 4
Exercise test results
Exercise
interval
(min)
Total
distance
(km)
Calories
expended
(kcal)
Metabolic
equivalents
achieved
Total steps
Placebo 38.6  5.9 4.0  0.7 386.8  94.3 6.2  1.2 4,267  908
Aspirin 36.3  6.9 3.9  0.8 367.3  77.8 4.6  1.8 4,586  776
All values are reported as mean  standard deviation.
Table 5
Blood markers
Variable Time point Placebo Aspirin Group
(p)
Time
(p)
Group  Time
(p)
PCT (s) 0.001 0.005 0.003
Baseline 151  71 151  71
Pre-exercise 151  65 250  74
Postexercise 114  24 210  82
Hb (g/dL) 0.022 0.644 0.219
Pre-exercise 17.2  1.9 16.1  1.5
Postexercise 16.7  1.4 16.3  1.1
Hct (%) 0.442 0.227 0.749
Pre-exercise 46.3  3.1 45.3  2.5
Postexercise 47.0  3.6 46.5  3.7
La (mmol/
L)
0.597 0.001 0.609
Pre-exercise 1.0  0.4 1.0  0.4
Postexercise 1.5  0.5 1.6  0.8
Endotoxin
(UE/mL)
0.637 0.011 0.835
Baseline 2.5  0.9 2.5  0.9
Pre-exercise 2.3  0.7 2.1  0.9
Postexercise 2.7  0.8 2.7  0.8
All values are presented as means  standard deviation.
Hb, hemoglobin; Hct, hematocrit; La, lactate; PCT, platelet closure time.
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(>39C) coupled with encapsulation likely reduced the evaporative
capacity of the skin and further reduced the gradient for heat
dissipation between the core, skin, and outside environment. After
exercise, both groups only reached approximately 80% of CVCmax.
Upright exercise in the heat has been previously reported to
attenuate skin blood ﬂow as core body temperature approaches
38C and that at high core body temperature, skin blood-ﬂow levels
are not maximal [40e43]. In addition, the reduced blood volume
from sweat loss further restricts skin blood ﬂow during exercise in
the heat [44,45]. The reduction in skin blood ﬂow in both groups is
more likely due to exercise in the uncompensable heat stress
environment than the result of the aspirin therapy.
Both dehydration and aspirin have been reported to cause
mucosal damage to the gut leading to endotoxin release and sub-
sequent increases in plasma TNF-a levels [23e25,29]. In our study,
endotoxin levels increased after the exercise in both the aspirin and
placebo trials. However, we do not believe that this is clinically
signiﬁcant or indicative of increased gut permeability following
exertion in the heat or related to the administration of aspirin as
none of the ﬁreﬁghters reported any adverse symptoms. This is
further supported by the nondetectable TNF-a levels in our study.
There are a few limitations to this study. First, our participants
were young, healthy, male ﬁreﬁghters. Previous reports showing
reductions in skin blood ﬂow were done in middle-aged men and
women, primarily aged>55 years [16,17,38]. To determine whether
age- or sex-related differences in skin blood-ﬂow responses under
uncompensable heat stress conditions following aspirin therapy
exist, this study should be repeated with older ﬁreﬁghters. Second,
we believe that uncompensable heat stress, rather than aspirin
therapy, is the major strain driving thermoregulatory changes
during work while wearing thermal-protective clothing. Additional
studies of an identical workload under compensable heat stress
conditions with andwithout aspirin therapy would allow us to fully
understand the thermoregulatory consequences of both aspirin
therapy and work under uncompensable heat stress conditions.
Finally, there is not a reliable system for real-time measurement
of skin blood ﬂow during exercise or while working under thermal-
protective clothing. Laser Doppler ﬂowmetry is a good measure-
ment of skin blood ﬂow because it is localized and speciﬁc to the
skin, allowsmeasurements frommultiple sites, and has a great deal
of agreement with other skin blood-ﬂow measurement in-
struments [46]. However, it does have its limitations in that it ishighly sensitive to motion and cannot be used during exercise and
is unable to measure absolute ﬂow. For this study, skin blood ﬂow
was measured at rest before exercise and immediately after exer-
cise, which we feel were adequate time points for this study. In
addition, the thermal-protective clothing would have made the
placement of the ﬂow probes on the forearms next to impossible
during the exercise phase. In this study, skin blood ﬂow was
normalized to the values attained during maximal vasodilation,
which has been determined to be a valid measurement technique
[46,47]. Despite these limitations, we feel that this method was
appropriate and accurate for this study.
Aspirin blunts platelet activation during uncompensable heat
stress. In this group of young, healthy, male ﬁreﬁghters, there were
no differences in skin blood ﬂow following exertion after 14 days of
aspirin therapy. We speculate that this may be due to the thermal-
protective clothing worn and uncompensable heat stress causing
severe thermoregulatory strain that supersedes any deleterious
effects of aspirin. These current data suggest that the effect of
aspirin on thermoregulation is not sufﬁcient to recommend against
its use among ﬁreﬁghters when indicated. However, more research
is needed to fully understand the mechanisms related to thermo-
regulation while wearing thermal-protective clothing during
uncompensable heat stress conditions.Conﬂicts of interest
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